guidance.fyi
Company, ticker, metric, guidance, or anything said

Concalls & earnings callsHealth X Platform Limited

Every summarised call, newest first. Latest is Q1 FY27, held 11 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Open full brief →

Health X delivered its highest-ever quarterly revenue, with strong growth in RetailerShakti and SastaSundar, as previous investments in geography, fulfillment, and the JITO private label begin to translate into momentum.

MetricThis quarterChangeFive-quarter trend
Revenue from Operations₹440 Cr58% Y-o-Y
Gross Margin7.8%—
EBITDAINR -15 crores—
PAT₹2 Cr—
Latest guidance
  • RetailerShakti expects to make positive EBITDA in Q3 FY27.
  • Aim to maintain gross margin above 8% for the full year.
  • July monthly revenue was INR150+ crores (subject to audit).
  • Long-term gross margin target is around 12%.
  • Plan to double market share in West Bengal from ~3-4% to ~7% in the next 2-3 years.
Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹281.29 Cr-24.9% YoY+2.8% QoQ₹-37.79 CrLoss widened YoYLoss narrowed QoQ₹-8.47Loss/share widened YoYLoss/share narrowed QoQ
Q2 FY25₹273.53 Cr-23.7% YoY+1.2% QoQ₹-154.79 CrLoss widened YoYTurned loss-making QoQ₹-34.40Loss/share widened YoYTurned negative QoQ
Q1 FY25₹270.29 Cr— YoY-11.9% QoQ₹40.97 Cr— YoY+89.9% QoQ₹9.79— YoY+89.4% QoQ
Q4 FY24₹306.67 Cr-2.1% YoY-18.1% QoQ₹21.57 CrTurned profitable YoYTurned profitable QoQ₹5.17Turned positive YoYTurned positive QoQ
Q3 FY24₹374.50 Cr+33.4% YoY+4.5% QoQ₹-3.23 CrLoss narrowed YoYLoss narrowed QoQ₹-0.23Loss/share narrowed YoYLoss/share narrowed QoQ
Call history
  • Q1 FY27Positive tone

    Health X delivered its highest-ever quarterly revenue, with strong growth in RetailerShakti and SastaSundar, as previous investments in geography, fulfillment, and the JITO private label begin to translate into momentum.

    Revenue from Operations
    ₹440 Cr58% Y-o-Y
    Gross Margin
    7.8%
    Pharmaceuticals & HealthcareVerified brief5 guidance items